I've decided not to reply or acknowledge posters l
Post# of 148306
Right now I see cydy as burning cash, and needing funds. However I know as a last resort they have more shares to issue.
On the flip side they have a very promising drug for multiple indications on diseases that aren't rare(yet). So revenue and profitability are possible, and having heard the independent doctors share actual customers excitement over using leronlimab vs daily pills adds validity to NPs message that some of us have grown immune to.
I would also keep an eye on any potential litigation from RP because that is still an unknown that could hamper progress if legal battles for IP ensues.(we just dont know)
Until then I'll stay long because the potential is great due to efficacy, patient need, ease of use, and possibility of partnership agreements.
But also watch for possible litigation, mgmt execution of strategy, funding strategy pre revenue and profitability post revenue.
Happy investing!